Healthcare Policy

Medicare Drug Costs: Your Out-of-Pocket Cap Jumps, But Are Negotiated Prices a Real Lifeline?

While the annual cap on what seniors pay for prescriptions is rising, new drug price negotiations offer a glimmer of hope amidst complex cost trends.

By Neil D'Monte, Palmelle Editorial Team · Reviewed by Neil D'Monte · 7 min read · 2026-07-02

SHORT ANSWER

Your Medicare Part D out-of-pocket drug cost cap is increasing to $2,100 in 2026, but negotiated drug prices are expected to start offering some relief for certain medications.

The direct answer

In 2026, Medicare Part D beneficiaries will see their annual out-of-pocket prescription drug cost cap increase to $2,100, a $100 rise from the $2,000 limit in 2025 [c5, c8, c9]. This increase is tied to the annual percentage increase in average expenditures for covered Part D drugs

"The CY 2026 annual out-of-pocket (OOP) threshold of $2,100, which is the original 2025 out-of-pocket cap of $2,000, adjusted based on the annual percentage increase in average expenditures for covered Part D drugs in the U.S. for Part D eligible individuals in the previous year (API)."
— CMS

. However, a significant shift is occurring as the Inflation Reduction Act mandates that Medicare begin negotiating prices for certain high-cost, single-source drugs starting in 2026 [c6, c7]. This means that while the *maximum* you might pay is going up, the *actual* prices for some medications could decrease due to these negotiations, potentially offsetting the higher cap for some individuals. The Centers for Medicare and Medicaid Services (CMS) finalized these policies, impacting how drug costs are managed for millions of seniors

CMS finalized its 2027 Medicare Advantage and Part D payment policies, projecting a net average 2.48% increase, or more than $13B in additional MA payments. The agency will also keep the 2024 MA risk adjustment model and exclude most unlinked chart review diagnoses from risk…
— Wall St Engine link

The Rising Tide of Out-of-Pocket Expenses

For many seniors, the annual out-of-pocket cap on prescription drugs is a critical figure. In 2026, this cap will be $2,100, up from $2,000 in 2025 [c5, c8, c9]. This $100 increase, while perhaps seeming minor to some, can represent a significant burden for individuals on fixed incomes. This adjustment is directly linked to the annual percentage increase in average spending on Part D drugs

"The CY 2026 annual out-of-pocket (OOP) threshold of $2,100, which is the original 2025 out-of-pocket cap of $2,000, adjusted based on the annual percentage increase in average expenditures for covered Part D drugs in the U.S. for Part D eligible individuals in the previous year (API)."
— CMS

. This means that as drug prices, on average, rise, so does the maximum amount beneficiaries might have to pay before reaching the cap. It’s a stark reminder that even with legislative efforts, the underlying cost pressures on prescription medications continue to exert influence on seniors' healthcare budgets. The expectation is that this cap will continue to be adjusted annually based on drug expenditure trends.

Negotiated Prices: A Glimmer of Hope or a Drop in the Ocean?

The Inflation Reduction Act (IRA) introduces a novel mechanism: Medicare negotiating drug prices directly [c6, c7]. Starting in 2026, the Centers for Medicare and Medicaid Services (CMS) is required to include certain high-cost, single-source drugs on formularies for which a maximum fair price has been established

"The IRA requires Part D sponsors to include on their formularies selected drugs for which a maximum fair price is in effect, starting in 2026."
— CMS

. This represents a fundamental shift, moving away from a system where prices were largely set by manufacturers. The negotiations are happening now, with the first impacts expected in 2026

"The Inflation Reduction Act requires that the Centers for Medicare and Medicaid Services (CMS) negotiate prices for Medicare and Medicaid for certain high-cost single-source drugs and biologics. The negotiations are to take place between this fall and next spring, and the first negotiated prices for Part D (outpatient) drugs will go into effect in 2026."
— Jeff Levin-Scherz, MD MBA FACP (Substack)

. While this is a significant step toward potentially lowering drug costs, it's important to note that negotiations will initially apply to a limited number of high-expenditure drugs. The actual savings will depend on which drugs are selected and the extent to which their prices are reduced, offering a potential offset to the rising out-of-pocket cap, but not necessarily a complete solution for all beneficiaries.

The Broader Healthcare Landscape: Insurers and Payments

It's crucial to understand that Medicare Part D operates within a larger ecosystem, particularly with the rise of Medicare Advantage plans. Recent CMS announcements about Medicare Advantage payments for 2027 project a net average increase of 2.48% [c1, c2, c3]. This is significantly higher than some anticipated, leading to a positive reaction from health insurers like UnitedHealth Group [c1, c3]. The industry views these rate increases as a substantial tailwind

Medicare Advantage just got a massive cash injection 💰 Trump admin finalizes Star Ratings overhaul — $18B in extra payments flowing to health insurers. This is a direct tailwind for the big MA players: $UNH , $HUM , $CVS , $ELV , $CNC all stand to benefit from higher reimbursement…
— Casey | Trade Tracs link

. While this doesn't directly impact Part D out-of-pocket caps, it highlights the financial dynamics within Medicare. Insurers are financially incentivized to manage costs and benefits within these plans, and changes in reimbursement rates can influence how prescription drug benefits are structured or offered within various Medicare plans. This complex financial environment underscores why understanding specific drug cost changes is vital.

A SCENE

Meet Eleanor, a retired librarian living on a fixed income in Des Moines. She relies on Medicare Part D to manage her conditions, taking three prescription medications daily. Her biggest worry is the unpredictable cost of her prescriptions, especially as she approaches the annual out-of-pocket cap. This year, she's been tracking her spending, mindful of the $2,000 limit. Come 2026, she knows that limit will rise to $2,100 [c8, c9]. That extra $100 is a concern. However, one of her medications, a biologic for her arthritis, is among the first group of high-cost drugs slated for Medicare price negotiation under the Inflation Reduction Act [c6, c7]. She's heard that the negotiated price for this drug might be significantly lower. If the savings on this one drug are substantial enough, it could potentially negate the impact of the increased cap, or even lead to overall savings for her year. She's also aware that her Medicare Advantage plan is part of a system where insurers are seeing favorable payment updates from CMS [c1, c2], which makes her wonder if those benefits will trickle down to her prescription drug coverage in any meaningful way beyond the negotiated prices. She plans to call her plan provider in late 2025 to understand precisely how the negotiated prices will affect her specific formulary and her out-of-pocket expenses for 2026.

Common mistakes

Assuming the negotiated drug prices will automatically result in lower out-of-pocket costs for everyone.
Negotiations apply to a select group of high-cost drugs. Savings will vary significantly based on an individual's specific medication needs and the extent of price reductions achieved.
Focusing solely on the out-of-pocket cap without considering the broader Medicare Advantage payment landscape.
Changes in Medicare Advantage reimbursement rates can indirectly influence benefit structures and the overall cost of prescription drug coverage within these plans, creating a more complex financial picture.
Treating the $100 increase in the out-of-pocket cap as insignificant.
For individuals on fixed incomes, even a $100 increase in annual healthcare expenses can represent a significant financial strain, impacting budgeting and access to other necessities.

PALMELLE'S VIEW

In our view, the narrative around Medicare drug costs is often oversimplified, pitting a rising out-of-pocket cap against the promise of negotiated prices. While the $2,100 cap is a concrete increase seniors will face [c8, c9], the true impact of drug price negotiations remains to be seen. The Inflation Reduction Act's mandate for CMS to negotiate prices for select high-cost drugs starting in 2026 [c6, c7] is a crucial development. It challenges the notion that drug costs are an unstoppable upward force. However, the industry's response, including potential shifts in Medicare Advantage payment structures [c1, c2, c3], suggests a complex interplay of forces. We need to look beyond the headline cap increase and understand which drugs will be affected by negotiations and how insurers might adapt.

BOTTOM LINE

Call your Medicare Part D plan provider in late 2025 to confirm how negotiated drug prices will specifically impact your prescription costs for 2026.

WHEN THIS CHANGES

The landscape of Medicare drug costs is dynamic. The specific impact of the $2,100 out-of-pocket cap and the effectiveness of negotiated drug prices will become clearer as CMS releases details on which drugs are selected for negotiation and their resultant prices. Beneficiaries should monitor announcements from CMS and their specific Medicare Part D plan providers throughout late 2025 and into 2026 for the most accurate information.

Frequently asked

What is the new out-of-pocket cap for Medicare Part D in 2026?

The annual out-of-pocket cap for Medicare Part D prescription drug costs will increase to $2,100 in 2026. This is a $100 increase from the $2,000 cap that was in place for 2025.

Will negotiated drug prices automatically lower my costs?

Not necessarily for all your medications. The Inflation Reduction Act allows Medicare to negotiate prices for a limited number of high-cost, single-source drugs starting in 2026. Your savings will depend on whether your specific prescriptions are among those negotiated and the degree of price reduction achieved.

How does the Medicare Advantage payment increase affect Part D costs?

The recent CMS announcement of a 2.48% average increase in Medicare Advantage payments for 2027 primarily impacts the financial health of health insurers offering these plans. While it doesn't directly change the Part D out-of-pocket cap, it could indirectly influence benefit designs or the availability of certain drug coverage options within Medicare Advantage plans.